Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering
Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering
SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Histogen Inc. (HSTO, the "Company" or "Histogen"), a drug development company for treatment of bacterial skin infections, today announced that it has filed voluntary petitions for relief under subchapter V of Chapter 11 of the U.S. Bankruptcy Code ("Chapter 11") in the United States Bankruptcy Court for the Southern District of California to confirm a plan of liquidation that will distribute all value to stakeholders, including shareholders.
Histogen intends to promptly propose and confirm a plan of liquidation and make distributions to the benefit of its estate. The Company announced on Sept. 18, 2023, that it had discontinued further development and would seek approve for a Plan of Dissolution.
Histogen is represented by DLA Piper, LLP as its legal counsel and Armanino LLP as its financial advisor.
ABOUT HISTOGEN
Histogen Inc. was a clinical-stage therapeutics company focused on developing potential clinical and preclinical drugs for a variety of antiapoptotic and anti-inflammatory effects.
CONTACT: MEDIA CONTACT Martin Stein AMF Media Group martin@amfmediagroup.com
SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Histogen Inc. (HSTO, the "Company" or "Histogen"), a drug development company for treatment of bacterial skin infections, today announced that it has filed voluntary petitions for relief under subchapter V of Chapter 11 of the U.S. Bankruptcy Code ("Chapter 11") in the United States Bankruptcy Court for the Southern District of California to confirm a plan of liquidation that will distribute all value to stakeholders, including shareholders.
聖地亞哥，2024年4月18日（GLOBE NEWSWIRE）——治療細菌性皮膚感染的藥物開發公司Histogen Inc.（HSTO，“公司” 或 “Histogen”）今天宣佈，它已根據美國破產法第11章（“第11章”）第五分章（“第11章”）向美國加利福尼亞南區破產法院提交了自願救濟申請，以確認一項清算計劃將所有價值分配給利益相關者，包括股東。
Histogen intends to promptly propose and confirm a plan of liquidation and make distributions to the benefit of its estate. The Company announced on Sept. 18, 2023, that it had discontinued further development and would seek approve for a Plan of Dissolution.
Histogen打算立即提出並確認清算計劃，並進行分配，使其財產受益。該公司於2023年9月18日宣佈，已停止進一步開發，並將尋求解散計劃的批准。
Histogen is represented by DLA Piper, LLP as its legal counsel and Armanino LLP as its financial advisor.
Histogen由DLA Piper, LLP作爲其法律顧問，Armanino LLP作爲其財務顧問。
ABOUT HISTOGEN
Histogen Inc. was a clinical-stage therapeutics company focused on developing potential clinical and preclinical drugs for a variety of antiapoptotic and anti-inflammatory effects.
關於組織原
Histogen Inc. 是一家臨床階段的治療公司，專注於開發具有各種抗凋亡和抗炎作用的潛在臨床和臨床前藥物。
CONTACT: MEDIA CONTACT Martin Stein AMF Media Group martin@amfmediagroup.com
聯繫人：媒體聯繫人 Martin Stein AMF Media Group martin@amfmediagroup.com
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧